Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Phase 3

Completed

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Placebo
Drug: Alirocumab
Drug: LMT

First Posted Date: 2012-08-13

Last Posted Date: 2019-03-18

Lead Sponsor: Sanofi

Target Recruit Count: 18924

Registration Number: NCT01663402

Locations: 🇺🇸
Investigational Site Number 840075, Atlanta, Georgia, United States
🇺🇸
Investigational Site Number 840231, Philadelphia, Pennsylvania, United States
🇺🇸
Investigational Site Number 840339, Philadelphia, Pennsylvania, United States

and more 1385 locations

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy

Phase 3

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Placebo
Drug: Aflibercept

First Posted Date: 2012-08-09

Last Posted Date: 2016-10-18

Lead Sponsor: Sanofi

Target Recruit Count: 332

Registration Number: NCT01661270

Locations: 🇨🇳
Investigational Site Number 156001, Beijing, China
🇨🇳
Investigational Site Number 156003, Beijing, China
🇨🇳
Investigational Site Number 156016, Chengdu, China

and more 34 locations

Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: SAR339658
Other: Placebo

First Posted Date: 2012-08-07

Last Posted Date: 2016-07-13

Lead Sponsor: Sanofi

Target Recruit Count: 28

Registration Number: NCT01659138

Locations: 🇺🇸
Investigational Site Number 840071, Rochester, New York, United States
🇺🇸
Investigational Site Number 840065, Sun City, Arizona, United States
🇺🇸
Investigational Site Number 840059, Mission Hills, California, United States

and more 38 locations

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Lantus (insulin glargine)
Drug: HOE901-U300 (new formulation of insulin glargine)

First Posted Date: 2012-08-07

Last Posted Date: 2015-06-01

Lead Sponsor: Sanofi

Target Recruit Count: 59

Registration Number: NCT01658579

Locations: 🇺🇸
Investigational Site Number 840002, Temecula, California, United States
🇺🇸
Investigational Site Number 840003, Portland, Oregon, United States
🇺🇸
Investigational Site Number 840001, Minneapolis, Minnesota, United States

Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: SAR125844

First Posted Date: 2012-08-06

Last Posted Date: 2016-02-17

Lead Sponsor: Sanofi

Target Recruit Count: 70

Registration Number: NCT01657214

Locations: 🇯🇵
Investigational Site Number 392001, Kashiwa-Shi, Japan
🇯🇵
Investigational Site Number 392004, Suita-Shi, Japan
🇯🇵
Investigational Site Number 392002, Sunto-Gun, Japan

and more 5 locations

Proof of Biological Activity of SAR100842 in Systemic Sclerosis

Phase 2

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: SAR100842
Drug: Placebo (for SAR100842)

First Posted Date: 2012-07-26

Last Posted Date: 2016-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 32

Registration Number: NCT01651143

Locations: 🇺🇸
Investigational Site Number 840001, Boston, Massachusetts, United States
🇫🇷
Investigational Site Number 250003, Lille, France
🇺🇸
Investigational Site Number 840007, New Brunswick, New Jersey, United States

and more 10 locations

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: CABAZITAXEL (XRP6258)
Drug: Prednisone
Drug: Ciprofloxacin
Drug: G-CSF (Granulocyte colony-stimulating factor)

First Posted Date: 2012-07-25

Last Posted Date: 2016-07-06

Lead Sponsor: Sanofi

Target Recruit Count: 45

Registration Number: NCT01649635

Locations: 🇧🇷
Investigational Site Number 006, Lajeado, Brazil
🇧🇷
Investigational Site Number 005, Porto Alegre, Brazil
🇧🇷
Investigational Site Number 002, São Paulo, Brazil

and more 3 locations

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Ezetimibe
Drug: Alirocumab
Drug: Placebo (for Alirocumab)
Drug: Placebo (for Ezetimibe)

First Posted Date: 2012-07-19

Last Posted Date: 2015-11-06

Lead Sponsor: Sanofi

Target Recruit Count: 103

Registration Number: NCT01644474

Locations: 🇺🇸
Investigational Site Number 840603, Overland Park, Kansas, United States
🇺🇸
Investigational Site Number 840601, Cincinnati, Ohio, United States
🇳🇱
Investigational Site Number 528602, Groningen, Netherlands

and more 5 locations

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo (for alirocumab)
Drug: Alirocumab
Drug: Lipid-Modifying Therapy (LMT)

First Posted Date: 2012-07-18

Last Posted Date: 2015-11-06

Lead Sponsor: Sanofi

Target Recruit Count: 316

Registration Number: NCT01644175

Locations: 🇺🇸
Investigational Site Number 840827, Mt. Pleasant, South Carolina, United States
🇺🇸
Investigational Site Number 840832, Southfield, Michigan, United States
🇺🇸
Investigational Site Number 840891, Mobile, Alabama, United States

and more 73 locations

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo (for alirocumab)
Drug: Alirocumab
Drug: Placebo (for ezetimibe)
Drug: Ezetimibe
Drug: Lipid Modifying Therapy (LMT)

First Posted Date: 2012-07-18

Last Posted Date: 2016-08-04

Lead Sponsor: Sanofi

Target Recruit Count: 720

Registration Number: NCT01644188

Locations: 🇺🇸
Investigational Site Number 840979, Los Angeles, California, United States
🇺🇸
Investigational Site Number 840966, Fall River, Massachusetts, United States
🇺🇸
Investigational Site Number 840946, Butte, Montana, United States

and more 123 locations

Home Terms & Conditions Privacy Policy